dragon pharma retatrutide Reta 🛑 People are buying Retatrutide

A new JAMA Medical News piece highlights 3 GLP-1based options likely to reshape weight management in 2026: 1) Orforglipron (oral, small-molecule GLP-1 RA) Once daily with or without food ~7.5% to 11.2% mean weight loss at 72 weeks (dose-dependent) Could be a real unlock for patients who are needle-averseor struggle with fasting dosing rules

Indeed, many of these side effects are potentially devastating for patients, especially when combined with other comorbidities or other side effects

Francis, R., Barton, M

Eli Lilly, the pharmaceutical company developing retatrutide, has progressed the compound into Phase 3 clinical trials, which are evaluating its efficacy and safety in larger populations across multiple indications, including obesity and type 2 diabetes